MarketInOut Stock Screener Log In | Sign Up
 

NewAmsterdam Pharma Co N.V.

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
NewAmsterdam Pharma Co N.V. stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,579.61 mln
Float76.26 mln
Earnings Date11/11/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-4.63
Highly reliable

1-Year Forecast

49.82
Transformational upside

Relative Strength

27 / 100
Underperforming

Debt / Equity

0.00
Debt-free

Pre-Tax Margin

-3,644%
Severely loss-making

Business Description

NewAmsterdam Pharma is a Netherlands-based drug development company focused on treating heart and metabolic conditions. Its lead drug, Obicetrapib, is a low-dose oral pill designed to reduce harmful cholesterol levels, currently being tested in multiple clinical trials both on its own and alongside another cholesterol-lowering agent. The company is also exploring whether Obicetrapib may offer benefits for patients with Alzheimer's disease.

Key Fundamentals

EPS-2.17
ROE-37.21
RPS0.06
ROIC-211
ROA-34.07
EBITDA, mln-259
EV / EBITDA-9.51
EV / EBIT-9.50
Revenue, mln7.12
EV / Revenue346

Quote Details

Last 19.71
Change -1.87 (-8.67%)
Open 21.39
Volume 2,311,139
Turnover 45,552,548
Average Volume 1,443,376

Financial Ratios

Pre-Tax Profit Margin-3,644
Leverage Ratio1.12
Current Ratio9.03
Price / Book4.53
Price / Tangible Book4.54
Debt / Equity0.00
Price / Sales419

Financial Strength

Altman Z-Score21.44
Piotroski F-Score 3 / 9
Beneish M-Score-4.63
1-Year Target Price49.82
Short Ratio10.36
Short % of Float18.64

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.61% 40 / 100   
1 Month -13.32% 25 / 100   
2 Months -33.57% 14 / 100   
6 Months -33.68% 19 / 100   
1 Year -43.69% 20 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog